


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula I



Formula I

wherein

X is CH₂, O or S;

R represents 1-3 substituents independently selected from H, (C₁₋₄)alkyl, (C₁₋₄)alkyloxy and halogen;

R₁ is (C₅₋₈)cycloalkyl;

R₂ is H or (C₁₋₄)alkyl;

R₃, R₃', R₄, R₄', R₅, R₅' and R₆' are independently hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen;

R₆ is hydrogen or (C₁₋₄)alkyl, optionally substituted with (C₁₋₄)alkyloxy, OH or halogen; or

R₆ forms together with R₇ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S;

R₇ forms together with R₆ a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; or

R₇ is H, (C₁₋₄)alkyl or (C₃₋₅)cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C₁₋₄)alkyloxy; or a pharmaceutically acceptable salt thereof.

2. (original) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R is H and R₁ is cyclopentyl or cyclohexyl.

3. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein X is CH₂ or O.
4. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
5. (Cancelled)
6. (Previously Presented) A pharmaceutical composition comprising a tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 1 together with a pharmaceutically acceptable carrier therefor.
7. (Cancelled)
8. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein X is CH₂ or O.
9. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 2, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
10. (Previously Presented) The tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative of claim 3, wherein R, R₂, R₃, R₃', R₄', R₅, R₅' and R₆' are H; R₄, R₆ and R₇ are independently H or (C₁₋₄)alkyl; or R₆ forms together with R₇ a 5- or 6-membered saturated heterocyclic ring and R₄ is H or (C₁₋₄)alkyl.
11. (Previously Presented) A method of treating pain in a patient in need of such treatment, comprising:
administering an effective amount of the compound according to claim 1.
12. (Currently Amended) A method of treating a disorder which is responsive to activating activation of a cannabinoid CB1 receptor in a patient in need thereof, wherein the disorder is selected from the group consisting of multiple sclerosis, spasticity, inflammation, glaucoma, nausea, emesis, loss of appetite, sleep disturbances, respiratory disorders, allergies, epilepsy,

migraine, cardiovascular disorders, neurodegenerative disorders, anxiety, traumatic brain injury and stroke, the method comprising:

administering to a patient an effective amount of the compound according to claim 1.